Repositioning Candidate Details
| Candidate ID: | R1080 |
| Source ID: | DB06689 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Ethanolamine oleate |
| Synonyms: | Ethamolin; Ethanolamine oleate; Monoethanolamine oleate; Oldamin |
| Molecular Formula: | C20H41NO3 |
| SMILES: | NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O |
| Structure: |
|
| DrugBank Description: | Ethanolamine oleate is a mild sclerosing agent. It is composed of ethanolamine, a basic substance, which when combined with oleic acid forms a clear, straw to pale yellow colored, deliquescent oleate. |
| CAS Number: | 2272-11-9 |
| Molecular Weight: | 343.5444 |
| DrugBank Indication: | For the treatment of patients with esophageal varices that have recently bled, to prevent rebleeding. |
| DrugBank Pharmacology: | When injected intravenously, ethanolamine oleate acts primarily by irritation of the intimal endothelium of the vein and produces a sterile dose-related inflammatory response. This results in fibrosis and possible occlusion of the vein. Ethanolamine oleate also rapidly diffuses through the venous wall and produces a dose-related extravascular inflammatory reaction. |
| DrugBank MoA: | The oleic acid component of ethanolamine oleate is responsible for the inflammatory response, and may also activate coagulation in vivo by release of tissue factor and activation of Hageman factor. The ethanolamine component, however, may inhibit fibrin clot formation by chelating calcium, so that a procoagulant action of ethanolamine oleate has not been demonstrated. |
| Targets: | Calcium ions chelator; Coagulation factor XII activator |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|